In 24 patients with hepatitic C virus (HCV) infection who participated in a randomized trial with alpha 2B interferon, HCV RNA analysis by the polymerase chain reaction with two separate primer sets was performed at weeks 0, 4, and 24 and during a follow-up period of 6 to 9 months. Prior to therapy all patients were HCV RNA positive. During therapy, HCV RNA decreased to an undetectable level (<1 chimpanzee infectious dose per ml) in nine patients at week 4. After week 4, no additional cases of HCV RNA disappearance (<1 chimpanzee infectious dose per ml) were observed. During follow-up, HCV RNA could not be detected in four of the six patients with a sustained alanine aminotransferase response. These results suggest the probable predictive value of HCV RNA levels for detecting the failure of therapy in an early stage of HCV infection.
In recent years, several randomized controlled studies were performed with alpha interferon (IFN) for the treatment of non-A, non-B hepatitis (NANBH) (9, 10, 13, 16, 19, 20) . The effect of IFN was evaluated by measuring the alanine aminotransferase (ALT) level in serum, which reflects the activity of liver disease.
Recently, the etiological agent for NANBH has been identified (6, 12) . The causative agent is now known as hepatitis C virus (HCV). The HCV genome is a positivestranded RNA molecule of about 9,400 nucleotides. Sequence homology among the known HCV strains is about 80% (3, 7, 14, 17, 21 ).
In the study described here, 24 patients were investigated for the presence of HCV RNA during and after IFN to 6931), which is identical to HCV-J (14) and HCV-BK (21) , and probe B (CATGACTCCCCTGATGCTGA; residues 6980 to 6999), which is identical to HCV-1 (7) . In all cases, HCV RNA was sought with both primer sets. Known HCV cDNA sequences (7, 14, 15, 18, 21) were used for selection of the primers and probes. The detection limit of our assay was 1 chimpanzee infectious dose per ml, as estimated with ANTIMICROB. AGENTS CHEMOTHER. Four patients, which were treated by the experimental scheme, stopped therapy before week 24. Two of them stopped therapy after 12 weeks and one stopped therapy after 20 weeks because their ALT levels remained elevated. One patient stopped therapy at week 20 because of noncompliance.
After 4 weeks of treatment, 9 of the 24 patients (5 in the standard scheme, 4 in the experimental scheme) showed a decrease in HCV RNA and HCV RNA became undetectable by both primer sets. At the end of therapy (week 24), HCV RNA reappeared in two patients (standard scheme) and after 6 to 9 months of follow-up in another three patients (one of the standard scheme, two on the experimental scheme). A normal ALT level (<30 U/liter) was observed at week 4, week 24, and the follow-up period in 8 (33%), 8 (33%), and 6 (25%) patients, respectively. A simultaneous absence of HCV RNA and a normal ALT level in the follow-up study was limited to four patients (two on the standard scheme, two on the experimental scheme) ( Table 1 ). The rapid decline in the amount of HCV RNA in responders between weeks 0 and 4 and the lack of an increase in the number of patients with HCV RNA present at a level of less than 1 chimpanzee infectious dose per ml after 4 weeks of treatment are of considerable interest; if confirmed, these findings may have implications for the duration of IFN therapy.
Similar results on the transient nature of HCV RNA disappearance, discrepancies between normalization of ALT levels and the presence of HCV RNA (1, 2) , and relapse within 6 months after termination of therapy were also observed by other investigators who used primers from the NC or NS4 region (4, 20) .
The use of two primer sets, NC and NS5, resulted in differences between the outcomes in plasma samples from five patients in our study. The HCV RNA was consistently undetectable with the NS5 primer set in one patient (nonresponder; standard scheme). In three other patients (nonresponders; two on the standard scheme, one on the experimental scheme), HCV RNA was not detected with the NS5 primer set at week 4 but was detected at week 24 or 48. During therapy, a change in HCV RNA positivity depending on the primer set was observed in one patient (nonresponder; experimental scheme).
The NC primer set was very suitable for monitoring HCV RNA levels during IFN therapy (7, 11, 14, 17, 21, 22) . The discongruent results for the two sets of primers at the beginning of and during therapy could not be the result of a reduced sensitivity of the assay (8) . In fact, these results are suggestive of the presence of HCV variants in these patients, and the individual sensitivities of these variants for IFN therapy are under investigation.
In conclusion, results of the present study suggest that monitoring of HCV RNA levels in the first months of IFN therapy may be of prognostic value for failure of therapy aimed at eradicating HCV RNA (in the present study, four patients [16%]). However, the normalization of ALT levels alone, as observed in an additional two patients, could be beneficial if they were sustained for long periods of time.
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